NDAINTRAVENOUSSOLUTION
Approved
Jan 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE (norepinephrine bitartrate) by Baxter is (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action). First approved in 2021.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Norepinephrine bitartrate in 5% dextrose is an intravenous solution containing a potent sympathomimetic amine used to restore and maintain blood pressure in acute hypotensive states. It operates through dual alpha-adrenergic (vasoconstriction) and beta-adrenergic (inotropic/coronary vasodilation) mechanisms. This is a critical care agent administered in intensive settings for hemodynamic support.
Peak14.8 years to LOE
Peak lifecycle stage suggests stable market position with mature commercial infrastructure and established hospital formulary presence, supporting sustained field and account management roles.
Mechanism of Action
(alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on norepinephrine bitartrate positions you in the high-stakes critical care market, requiring deep hospital relationships and ICU protocol expertise rather than field-based primary care sales. This product offers stable, long-term career trajectory in hospital-focused commercial and medical affairs roles with minimal disruption risk through 2041.
Hospital Account ManagerCritical Care Sales Specialist
Worked on NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.